Results 111 to 120 of about 4,599 (158)

Technology Access and Preferences for Smartphone App Interventions to Optimize Iron Chelation Therapy Adherence Among Adolescents, Young Adults, and Parents of Children Receiving Chronic Transfusions: Cross-Sectional Survey Study. [PDF]

JMIR Pediatr Parent
Reddy P, Locke M, Badawy S.
europepmc   +1 more source

Deferiprone ameliorates cisplatin induced peripheral neurotoxicity via ferritinophagy adjustment. [PDF]

Sci Rep
Seddiek H, Hanna M, Hamoud AEM, Elbaset MA, Akabawy AMA, Kotb MZ, Khalifa MM.   +6 more
europepmc   +1 more source

New Approaches and Strategies for the Repurposing of Iron Chelating/Antioxidant Drugs for Diseases of Free Radical Pathology in Medicine. [PDF]

Antioxidants (Basel)
Kontoghiorghes GJ.
europepmc   +1 more source

Impact of Sappan Wood Extract as Iron Chelator Adjuvant on Iron Concentration and Macrophage Polarization in Rat Spleen. [PDF]

Iran J Med Sci
Ghozali M, Safitri R, Khristian E, Ainni AP, Kuntana YP, Bashari MH, Purnama JN.   +6 more
europepmc   +1 more source

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.

JAMA Neurol
Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C, Goh AMY, Kalinowski P, Kyndt C, Lai R, Lim YY, Maruff P, O'Brien TJ, Rowe C, Salvado O, Schofield PW, Spino M, Tricta F, Wagen A, Williams R, Woodward M, Bush AI.   +25 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Deferiprone

Annals of the New York Academy of Sciences, 2010
Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, ANTONIO GIULIO, ROGGERO, SIMONA, I. Salussolia, D. Massano, M. Serra, F. Longo   +5 more
openaire   +3 more sources

Deferiprone

Reactions Weekly, 2012
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J. Cada, Terri L. Levien, Danial E. Baker   +2 more
  +4 more sources